Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share. The gross proceeds from this offer...
Allogene Therapeutics (NASDAQ: ALLO ) commences a $450M public offering of common stock. More news on: Allogene Therapeutics, Inc., Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock. In addition, Allogene expects to grant the underwriters a 30-day o...
ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) In the Ongoing Study, 22 Patients were Evaluable for Safety and 19 Patients Were Evaluable for Efficacy with ...
Webinar Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today a...
Shares of Allogene Therapeutics (NASDAQ: ALLO) gained over 33% in early trading Thursday after the company reported preliminary data from a phase 1 clinical trial. The results will be featured in an abstract to be presented at the American Society of Clinical Oncology (ASCO) meeting at the e...
Gainers: Applied DNA Sciences (NASDAQ: APDN ) +51% . More news on: Applied DNA Sciences, Inc., Akers Biosciences, Inc., Glory Star New Media Group Holdings Limited, Stocks on the move, , Read more ...
Applied DNA Sciences (NASDAQ: APDN ) +71% after receiving FDA emergency use authorization for COVID-19 test. More news on: Applied DNA Sciences, Inc., AIM ImmunoTech Inc., Immunic, Inc., Stocks on the move, , Read more ...
Allogene Therapeutics (NASDAQ: ALLO ) jumped 26% AH, after the company announced the release of the abstract related to an upcoming oral presentation at the American Society of Clinical Oncology Annual Meeting. More news on: Allogene Therapeutics, Inc., Healthcare stocks...
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host Disease Abstract Based on Data Cutoff in January 2020 Represents Limited Data Set of Nine Evaluable Patients Treated at Lower Dose (39mg) AL...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...